Kaye Randall's Form 4 filing
Longboard Pharmaceuticals, Inc. (LBPH) · filed Aug 13, 2024
- Accession no.
- 0000950170-24-096496
- Filed
- Aug 13, 2024
- Trade date
- Jan 23-Aug 12, 2024
- Filing delay
- 203 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market purchases total $2.48K. Open-market sales total $580.9K. It was filed 203 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kaye RandallCIK 0001350416 | Officer (CMO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 23, 2024 | Common Stock | PPurchaseAcquired | +100 | $24.82 | +$2,482 | 100 | Indirect | |
| Jun 25, 2024 | Common Stock | SSaleDisposed | −100 | $20.87 | −$2,087 | 0 | Indirect | |
| Aug 12, 2024 | Common Stock | MOption exerciseAcquired | +16,667 | $4.35 | +$72,501.45 | 34,587 | Direct | |
| Aug 12, 2024 | Common Stock | SSaleDisposed | −10,476 | $34.55F4 | −$361,945.8 | 24,111 | Direct | |
| Aug 12, 2024 | Common Stock | SSaleDisposed | −6,191 | $35.03F5 | −$216,870.73 | 17,920 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 12, 2024 | Common Stock | MOption exerciseDisposed | −16,667 | $0.00 | $0 | 129,633 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F4
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.88 to $34.87, inclusive. The reporting person undertakes to provide Longboard Pharmaceuticals, Inc., any security holder of Longboard Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 4 and 5 to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.88 to $35.32, inclusive.
Referenced by the price of 1 transaction in Table I.